Next Science Ltd
ASX:NXS

Watchlist Manager
Next Science Ltd Logo
Next Science Ltd
ASX:NXS
Watchlist
Price: 0.135 AUD -5.26% Market Closed
Market Cap: 39.4m AUD
Have any thoughts about
Next Science Ltd?
Write Note

Next Science Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Next Science Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Next Science Ltd
ASX:NXS
Cost of Revenue
-$5.9m
CAGR 3-Years
-125%
CAGR 5-Years
-74%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Cost of Revenue
-AU$37.6m
CAGR 3-Years
-18%
CAGR 5-Years
-12%
CAGR 10-Years
-17%
Polynovo Ltd
ASX:PNV
Cost of Revenue
-AU$5.5m
CAGR 3-Years
-52%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
Cost of Revenue
-AU$42.2m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Anteris Technologies Ltd
ASX:AVR
Cost of Revenue
-AU$1.6m
CAGR 3-Years
16%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Ansell Ltd
ASX:ANN
Cost of Revenue
-$994.5m
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
0%
No Stocks Found

Next Science Ltd
Glance View

Market Cap
39.4m AUD
Industry
Health Care

Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.

NXS Intrinsic Value
1.454 AUD
Undervaluation 91%
Intrinsic Value
Price

See Also

What is Next Science Ltd's Cost of Revenue?
Cost of Revenue
-5.9m USD

Based on the financial report for Dec 31, 2023, Next Science Ltd's Cost of Revenue amounts to -5.9m USD.

What is Next Science Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-74%

Over the last year, the Cost of Revenue growth was -132%. The average annual Cost of Revenue growth rates for Next Science Ltd have been -125% over the past three years , -74% over the past five years .

Back to Top